Melatonin has become a widely used sleep aid for children globally. A recent narrative review, published in the World Journal of Pediatrics on April 30, 2025, by researchers at Boston Children's Hospital, examined the increasing global use of melatonin among pediatric populations. The review synthesizes clinical evidence on effectiveness, safety, and real-world use patterns.
Key Findings
- Increased Use: Melatonin use among children has risen significantly over the past decade, particularly in countries where it is sold over-the-counter.
- Effectiveness in Specific Groups: Strong evidence supports short-term effectiveness for children with neurodevelopmental disorders, such as autism and attention-deficit hyperactivity disorder. In these cases, melatonin can reduce sleep-onset delay, increase total sleep time, and improve caregiver quality of life.
- Limited Data for Typically Developing Children: Evidence for typically developing children is sparse and inconsistent. Most randomized trials are short-term and involve older children or adolescents, which limits conclusions regarding younger children where melatonin use is also increasing.
- Lack of Long-Term Safety Data: Long-term safety data are largely unavailable, leaving questions about potential effects on puberty, immune function, metabolism, and neurological development unresolved.
- Product Variability and Safety Concerns: Analyses of commercial melatonin products have shown inconsistencies between labeled and actual melatonin content. Some products contain multiple times the stated dose, and others include unintended compounds like serotonin. Pediatric poison control data also indicate a sharp rise in accidental melatonin ingestions, particularly among young children, often linked to gummy formulations and improper storage.
Implications and Recommendations
The review suggests that melatonin should not be regarded as a simple solution for childhood sleep problems. While it may play a role in specific, carefully selected cases under medical supervision, it should not replace comprehensive sleep evaluations or behavioral interventions. Clinicians and caregivers are encouraged to recognize melatonin as a biologically active hormone rather than a benign supplement.
Behavioral sleep interventions, such as consistent routines, reduced screen exposure, and age-appropriate expectations, are recommended as the primary treatment for childhood insomnia. If melatonin use is considered, it should be at the lowest effective dose, for the shortest possible duration, and under medical guidance. The review also calls for improved regulation of pediatric melatonin products, clearer labeling standards, and further long-term clinical studies to ensure safe, effective, and evidence-based support for children's sleep health.